Patent ID: 8460674
Filing Date: 2013-06-11
Classification: A61K,C07K,C12N

Abstract:
1. A pharmaceutical composition comprising an isolated HSV-1polypeptide, wherein the HSV-1polypeptide comprises an immunogenic portion of VP16, and a pharmaceutically acceptable carrier, wherein the polypeptide consists of amino acids: 64-160 , 90-99, 141-240, 187-199, 191-203, 215-227, 218-320, 219-230, 381-490, 479-489, 479-488, 480-488 or 477-490 of VP16 (SEQ ID NO: 1) and up to 50 amino acids of adjacent sequence of the original protein of SEQ ID NO: 1; optionally fused to a heterologous polypeptide, wherein the heterologous polypeptide is selected from glycoprotein L (SEQ ID NO: 2), glycoprotein K (SEQ ID NO: 3), or a fragment or combination thereof.